Galderma: brands it owns and its ownership tree
Galderma (SIX: GALD) is a publicly listed company headquartered in Zug, Switzerland that owns 2 consumer brands.[1]
Galderma Group AG is a Swiss dermatology company, listed on the SIX Swiss Exchange since 2024, that describes itself as a pure-play dermatology category leader. It sells injectable aesthetics (Restylane, Sculptra, Dysport), prescription therapeutic dermatology (Nemluvio, Soolantra, Epiduo) and consumer skincare. Only the consumer skincare brands are recorded here; the injectables and prescription medicines have no matching category on this site.
-
brands owned
-
1
categories
-
0
acquisitions recorded
-
0
divestitures recorded
Company facts
- Legal name
- Galderma Group AG
- Type
- publicly listed company · see all publicly listed company owners
- Headquarters
- 🇨🇭 Zug, Switzerland
- Tickers
- SIX: GALD
- Website
- www.galderma.com
- Last verified
- · 1 sources
Galderma in numbers
- Galderma owns 2 consumer brands tracked here across 1 top-level categories; the largest is personal care & beauty with 2 brands.[1]
- 2 of its brands originated outside Switzerland.
Everything Galderma owns
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Full-screen interactive tree →
Brand portfolio by category
Recent changes to this record
Frequently asked questions
What brands does Galderma own?
Galderma owns 2 consumer brands tracked here, including Cetaphil and Alastin.
Is Galderma a Swiss company?
Yes. Galderma is headquartered in Zug, Switzerland.
Who owns Galderma?
Galderma is a publicly listed company owned by its shareholders; it trades as GALD on the SIX.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Galderma Annual Report 2025 — Galderma Group AG, Annual report, published 4 March 2026; retrieved 3 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.